Tissue Modeling & Drug Development Shared Resources Core

组织建模

• 批准号: 10762125
• 负责人: PAUL OKUNIEFF
• 金额: $ 16.09万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-17 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762125
• 关键词: Address; African American; Archives; Basic Science; Biocompatible Materials; Bioinformatics; Black race; California; Caring; Cell Line; Chemistry; Collaborations; Collection; Complex; Conscious; Data; Databases; Development; Development Plans; Disparity; Education; Ensure; Evaluation; FDA approved; First Independent Research Support and Transition Awards; Florida; Funding; Future; Genomics; Goals; Hispanic; Human; Implant; Individual; Institution; Latinx; Latinx population; Lead; Leadership; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Medical Research; Mentorship; Methodology; Mission; Modeling; Molecular; Normal tissue morphology; Organoids; Outcome; Pathologic; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pilot Projects; Plasma; Population; Prostate; RNA; Race; Research; Research Personnel; Research Project Grants; Residual state; Resource Sharing; Resources; Role; Sampling; Scientist; Serum; Specimen; Technology; Testing; Tissue Banks; Tissue Model; Tissue Sample; Tissues; Translational Research; Tumor Tissue; Universities; anticancer research; biobank; cancer health disparity; cancer type; career development; clinical database; clinical translation; crosslink; drug development; ethnic diversity; experience; genomic data; health equity; member; neoplasm registry; novel; pancreatic cancer patients; patient derived xenograft model; patient population; racial diversity; recruit; repository; research and development; response; skills; success; technology development; tumor; virtual; Address; African American; Archives; Basic Science; Biocompatible Materials; Bioinformatics; Black race; California; Caring; Cell Line; Chemistry; Collaborations; Collection; Complex; Conscious; Data; Databases; Development; Development Plans; Disparity; Education; Ensure; Evaluation; FDA approved; First Independent Research Support and Transition Awards; Florida; Funding; Future; Genomics; Goals; Hispanic; Human; Implant; Individual; Institution; Latinx; Latinx population; Lead; Leadership; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Medical Research; Mentorship; Methodology; Mission; Modeling; Molecular; Normal tissue morphology; Organoids; Outcome; Pathologic; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pilot Projects; Plasma; Population; Prostate; RNA; Race; Research; Research Personnel; Research Project Grants; Residual state; Resource Sharing; Resources; Role; Sampling; Scientist; Serum; Specimen; Technology; Testing; Tissue Banks; Tissue Model; Tissue Sample; Tissues; Translational Research; Tumor Tissue; Universities; anticancer research; biobank; cancer health disparity; cancer type; career development; clinical database; clinical translation; crosslink; drug development; ethnic diversity; experience; genomic data; health equity; member; neoplasm registry; novel; pancreatic cancer patients; patient derived xenograft model; patient population; racial diversity; recruit; repository; research and development; response; skills; success; technology development; tumor; virtual

ABSTRACT – TISSUE MODELING & DRUG DEVELOPMENT CORE (SHARED RESOURCE) The goal of the Florida-California Cancer Research, Education, & Engagement (CaRE2) Health Equity Center’s Tissue Modeling and Drug Development Core (TMDDC) is to provide a growing archive of fixed and living tissues that will support the mission of the CaRE2 Center. In the first funding period (Cycle 1), we were highly successful in gaining access for FAMU and CaRE2 researchers to annotated tissues from Black/African American (B/AA) and Hispanic/Latinx (H/L). In total, the TMDDC now has regulatory compliant access across the partnership to cancer cases including pancreatic cancer blocks (295 B/AA, 306 H/L), pancreatic cancer plasma/serum (136 B/AA, 53 H/L), prostate cancer blocks (548 B/AA, 195 H/L), and prostate plasma/serum (595 B/AA, 92 H/L). Also, the TMDDC facilitated creation or identification of 4 new patient-derived xenografts (PDX) from B/AA patients with pancreatic cancer for studies at FAMU and USC. The TMDDC will continue to develop a robust, well-annotated biorepository of fixed and living tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 investigators. The TMDDC will consist of existing institutional, nationally shared, and future-conscious biorepository resources. The short-term goals of the TMDDC are to provide the necessary tissue samples for the three projects included in this application, while preparing for the future needs of the existing and upcoming CaRE2 Center projects. The TMC will address the challenge of recruiting B/AA and H/L individuals in medical research and the limited supply of quality biospecimens and genomic data for these populations. Our specific aims are to: Aim 1. Advance our existing virtual and physical repositories that will increasingly provide biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types and many tissue models are relevant to outcomes in disparities research. The broad types of tissues and data required to study these complex issues make acquisition of a fully satisfactory repository beyond the scope of any single institution. Therefore, we will develop capabilities to collect or acquire novel diverse and well annotated specimens through our institutional resources and other resources. Aim 2. Acquire living tumor tissue for drug development. PDXs have proven to better predict human drug responses than historically used cell-line derived studies. Development of these PDXs has the potential to facilitate rapid drug development, including testing response as a function of race/ancestry. The TMDDC will advance the existing Cycle 1 developed tissue repository at FAMU. The TMDDC will advance on the existing living tissue repository at FAMU. By achieving these aims, we will: (1) enhance cancer disparities tissue-modeling research; (2) expand cancer disparities resources for CaRE2 researchers, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU. Evaluation will be based on adequate provision of project-required specimens/resources and by success in transferring drug development technology and knowhow to FAMU.

摘要 - 组织建模与药物开发核心（共享资源） 佛罗里达 - 加利福尼亚癌症研究，教育与参与的目标（CARE2）健康权益中心的 组织建模和药物发育核心（TMDDC）是提供固定和活组织的日益增长的档案 这将支持Care2中心的任务。在第一个资金期（第1周期）中，我们非常成功 为了获得FAMU和CARE2研究人员的访问权，来自黑人/非裔美国人的注释组织（B/AA） 和西班牙裔/拉丁裔（H/L）。总的来说，TMDDC现在在整个合作伙伴关系中都具有规范的访问权限 癌症病例包括胰腺癌阻滞（295 b/aa，306 h/l），胰腺癌等离子体/血清（136 B/AA，53 h/l），前列腺癌阻滞（548 b/aa，195 h/l）和前列腺等离子体/血清（595 b/aa，92 h/l）。 此外，TMDDC从B/AA准备了4个新的患者衍生Xenographictic（PDX）的创建或鉴定 胰腺癌患者在FAMU和USC进行研究。 TMDDC将继续发展一个强大的 来自佛罗里达州和种族多样化的固定组织样本和活组织样本的井井有条的生物座 加利福尼亚州的患者群体，并将其提供给CARE2调查人员。 TMDDC将包括 现有的制度，全国共享和未来意识的生物座席资源。短期目标 TMDDC将为本应用程序中包含的三个项目提供必要的组织样本，而 为现有和即将到来的CARE2中心项目的未来需求做准备。 TMC将解决 在医学研究中招募B/AA和H/L个人的挑战以及质量有限的供应 这些人群的生物测量和基因组数据。我们的具体目的是：目标1。推进我们现有的 虚拟和物理存储库将增加来自潜水肿瘤存储库的生物测量 通过CARE2中心提供的单个访问点。许多癌症类型和许多组织模型是 与差异研究结果有关。研究这些复合物所需的广泛类型的组织和数据 问题使得在任何单个机构范围之外都获得了完全满意的工厂存储库。所以， 通过我们 机构资源和其他资源。 AIM 2。获取活肿瘤组织以进行药物发育。 PDXS 事实证明，比历史上使用的细胞系衍生研究更好地预测了人类药物反应。发展 这些PDX有可能促进快速的药物开发，包括测试反应作为 种族/血统。 TMDDC将推进现有的周期1在FAMU开发组织存储库。 TMDDC 将在FAMU的现有生活组织存储库上前进。通过实现这些目标，我们将：（1）增强 癌症分布组织模型研究； （2）扩大CARE2研究人员的癌症分布资源， （3）确保持续关注与FAMU转移知识，技术和合作。 评估将基于足够的项目要求的标本/资源，并取得成功 转移药物开发技术并知道如何进行FAMU。